Prevalence of extended spectrum beta-lactamase production among Klebsiella pneumoniae strains isolated at a University Hospital in Turkey

Journal of Chemotherapy

Volumn 12, Issue 2, 2000, Pages 145-152

  Gulay, Zeynep ^a   Thompson, C J ^b   Yulug N ^a   Amyes, S G B ^b  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Antibiotic susceptibility; Extended spectrum lactamase; Klebsiella pneumoniae; Plasmid analysis

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; IMIPENEM; PENICILLIN DERIVATIVE; ANTIINFECTIVE AGENT; BETA LACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; KLEBSIELLA PNEUMONIAE; NONHUMAN; PREVALENCE; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL; BIOSYNTHESIS; CHEMISTRY; CLASSIFICATION; CROSS INFECTION; ENTEROBACTER INFECTION; ENZYMOLOGY; HUMAN; ISOELECTRIC FOCUSING; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CROSS INFECTION; HUMANS; ISOELECTRIC FOCUSING; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PREVALENCE; TURKEY;

EID: 0034167140     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2000.12.2.145     Document Type: Article

References (32)

1. 1 Smith CE, Tilteman BS, Howell AW, Longfield RN, Jorgensen JH. Failure of ceftazidime amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended spectrum β-lactamase. Antimicrob Agents Chemother 1990; 34: 1290-3.
2. 2 Nauovski L, Quinn JP, Miyashira D et al. Outbreak of ceftazidime resistance due to a novel extended spectrum β-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 1992; 36: 1991-6.
3. 3 Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late generation cephalosporins. Ann Intern Med 1993; 119: 353-8.
4. 4 Karas JA, Pillay DG, Muckert D, Sturm AW. Treatment failure due to extended spectrum β-lactamase. J Antimicrob Chemother 1996; 37: 203-4.
5. 5 Knothe H, Shah P, Krenery V, Aratal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315-7.
6. 6 Jarlier V, Nicholas MH, Fournier G, Philippon A. Extended broad spectrum β-lactamases conferring resistance to newer beta-lactam agents in Enterobacteriaceae, hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-78.
7. 7 Liu PY, Gur D, Hall LM, Livermore PM. Survey of the prevalence of β-lactamases amongst 1000 Gram negative bacilli isolated consecutively at the Royal London Hospital. J Antimicrob Chemother 1992; 30: 429-47.
8. 8 Vatsopoulos AC, Phillippon A, Tzouvelekis LS, Komninou Z, Legakis NJ. Prevalence of transferable SHV-5 type β-lactamase in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Antimicrob Chemother 1990; 26: 635-48.
9. 9 Schoonveldt JM, Nimmo GR, Giffard P. Detection and characterisation of extended spectrum β-lactamases in Klebsiella pneumoniae causing nosocomial infection. Pathology 1998; 30: 164-8.
10. 10 Yuan M, Aucken H, Hall LM, Pitt TL, Livermore DM. Epidemiological typin of klebsiellae with extended-spectrum β-lactamases from European intensive care units. J Antimicrob Chemother 1998; 41: 527-39.
11. 11 DuBois SK, Marriott MS, Amyes SGB. TEM and SHV derived extended spectrum β-lactamases; relationship between selection, structure and function. J Antimicrob Chemother 1995; 35: 7-22.
12. 12 Amyes SGB. Genes and spectrum, the theoretical limits. Clin Infect Dis 1998; 27 (suppl 1): S21-8.
13. 13 Nordmann P. Trends in β-lactam resistance among Enterobacteriaceae. Clin Infect Dis 1998; 27 (suppl 1): S100-7.
14. 14 Stapleton PD, Shannon K, French GL. Carbapenem resistance in Escherichia coli associated with plasmid determined CMY-4 β-lactamase production and loss of an outer membrane protein. Antimicrob Agents Chemother 1999; 43: 1206-10.
15. 15 Gur D, Pitt TL, Hall LMC, Akalin HE, Livermore DM. Diversity of klebsiellae with extended-spectrum β-lactamases at a Turkis University Hospital. J Hosp Infect 1995; 22: 163-78.
16. 16 Bachmann BJ. Pedigrees of some mutant strains of Escherichia coli. Bact Rev 1992; 36: 525-57.
17. 17 Working Party of the British Society for Antimicrobial Chemotherapy. A guide to sensitivity testing. J Antimicrob Chemother 1991; 37 (suppl D): 1-47.
18. 18 Thomson CJ, Amyes SGB. Molecular epidemiology of the plasmid-encoded TEM-1 β-lactamase in Scotland. Epidemol Infect 1993; 110: 117-25.
19. 19 Nandivada LS, Amyes SGB. Plasmid mediated β-lactam resistance in pathogenic Gram-negative bacteria isolated in South India. J Antimicrob Chemother 1990; 26: 279-90.
20. 20 Takahashi S, Nagano Y. Rapid procedure for isolation of plasmid DNA and application to epidemiological analysis. J Clin Microbiol 1984; 20: 608-13.
21. 21 Matthew M, Harris AM, Marshall MJ, Ross GW. Th use of analytical isoelectric focusing for the detection and identification of β-lactamases. J Gen Microbiol 1975; 88: 169-78.
22. 22 Amyes SGB, Payne DJ, DuBois SK. Plasmid mediated β-lactamases responsible for penicillin and cephalosporin resistance. J Med Microbiol 1992; 36: 4-29.
23. 23 Sirot DL, Goldstein FW, Soussy CJ et al. Resistance to cefotaxime and seven other β-lactams in members of the family Enterobacteriaceae, a three-year survey in France. Antimicrob Agents Chemother 1993; 36: 1677-81.
24. 24 Phillippon A, Arlet G, Lagrange PH. Origin and impact of plasmid-mediated extended spectrum β-lactamases. Eur J Clin Microbiol Infect Dis 1994; 13(suppl1): S17-29.
25. 25 D'Agata E, Venkatraman L, DeGirolami P, Weigel L, Samore M, Tenover F. The molecular and clinical epidemiology of Enterobacteriaceae producing extended-spectrum β-lactamase in a tertiary care hospital. J Infect 1998; 36: 279-85.
26. 26 Bedenic B, Zagar Z. Extended-spectrum β-lactamases in clinical isolates of Klebsiella pneumoniae from Zagreb, Croatia. J Chemother 1998; 10: 449-59.
27. 27 Shannon K, Stapleton P, Xiang X et al. Extended-spectrum β-lactamase producing Klebsiella pneumoniae strains causing nosocomial outbreaks of infection in the United Kingdom. J Clin Microbiol 1998; 36: 3105-10.
28. 28 Revathi G, Shannon KP, Stapleton PD, Jain BK, French GL. An outbreak of extended spectrum β-lactamase producing Salmonella seftenberg in a burns ward. J Hosp Infect 1998; 40: 295-302.
29. 29 Nüesch-Inderbinen MT, Kayser FH, Hachler H. Survey and molecular genetics of SHV β-lactamases in Enterobacteriaceae in Switzerland: two novel enzymes: SHV-11 and SHV-12. Antimicrob Agents Chemother 1997; 41: 943-9.
30. 30 Kim J, Kwon Y, Pai H, Kim JW, Cho DT. Survey of Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: prevalence of SHV-12 and SHV-2a in Korea. J Clin Microbiol 1998; 36: 1446-9.
31. 31 Bauernfeind A, Chong Y, Schweighart S. Extended-broad spectrum β-lactamase in Klebsiella pneumoniae including resistance to cephamycins. Infection 1989; 17: 316-321.
32. 32 Horii T, Arakawa Y, Ohita M, Ichiyama S, Wacharotayankun R, Kato N. Plasmid-mediated Amp C type β-lactamase isolated from Klebsiella pneumoniae confers resistance to broad spectrum β-lactams including moxalactam. Antimicrob Agents Chemother 1993; 37: 984-90.